Fate Therapeutics
FATE
40 hedge funds and large institutions have $60.8M invested in Fate Therapeutics in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 7 closing their positions.
154% more capital invested
Capital invested by funds: $23.9M → $60.8M (+$36.9M)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
3% more funds holding
Funds holding: 39 → 40 (+1)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$11.7M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.43M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$1.38M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73.1K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$71.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$607K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$351K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$187K |
| 4 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$143K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$131K |
FATE Hedge Fund Activity: Q3 2016 in Review
40 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2016, worth a combined $60.8M — up 154% from $23.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FATE positions and 7 closed out — a net gain of 1 holder — while 10 added to existing stakes and 13 trimmed.
The largest buyer was Franklin Resources, adding an estimated $11.7M. The largest seller was Belmont Global Advisors, cutting an estimated $607K.
- 40 institutional investors held Fate Therapeutics (FATE) as of Q3 2016, up from 39 in Q2 2016.
- Funds reported $60.8M of Fate Therapeutics stock for Q3 2016, up 154% quarter-over-quarter.
- 8 funds opened new Fate Therapeutics positions in Q3 2016 and 7 closed out, a net change of +1 holder.
- The largest Fate Therapeutics buyer in Q3 2016 was Franklin Resources, an estimated $11.7M added.
- The largest Fate Therapeutics seller in Q3 2016 was Belmont Global Advisors, an estimated $607K sold.
Based on aggregated 13F filings for Q3 2016.